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ABSTRACT
Endothelial and Smooth Muscle-Dependent Vascular Reactivity In Immature
Arterialized Collateral Capillaries
Caitlin Koeroghlian
Peripheral arterial occlusive disease (PAOD) occurs due to the build up of atherosclerotic
plaque and reduces blood flow to cause chronic ischemia. Patients with PAOD may experience
intermittent claudication, or the pain in limb skeletal muscles due to a decease in blood flow.
Collateral arteries can act as a natural bypass and improve blood flow to hypoxic tissue by
creating an alternate route for blood to flow, but not all patients with PAOD have pre-existing
collateral networks. Animal studies indicate that tissues without pre-existing collateral networks
can form de novo collaterals from capillaries following occlusion of a feed artery. Unfortunately,
theses de novo collaterals, termed arterialized collateral capillaries (ACCs) lack functional
vasodilation at day-7 following feed artery occlusion. To induce the formation of ACCs, we
ligated the lateral feed artery in the spinotrapzeius muscle in Balb/c mice. We evaluated the
potential mechanism of impaired functional vasodilation in immature arterialized collateral
capillaries (7 days following occlusion) by measuring endothelial-dependent vasodilation to
bradykinin and endothelial-independent vasodilation to isoproterenol and sodium nitroprusside.
Vasodilation to both the endothelial-dependent and endothelial-independent vasodilators was
impaired in the immature ACCs as compared to the terminal arterioles on the unoperated sham
side. Similar responses to the endothelial cell and smooth muscle cell-dependent vasodilations
suggest that impaired functional vasodialtion is due to impaired vascular smooth muscle cell
function, which is consistent with our preivous research. We speculate that the SMCs of the
ACCs are immature and may still be remodeling, rearranging, or modulating phenotype in the
newly formed collaterals. Determining factors to induce mature arterialized collateral capillaries
in patients with PAOD lacking pre-existing collateral netoworks could reduce ischemia and
improve prognosis.
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INTRODUCTION
Clinical Relevance
Peripheral arterial occlusive
ve disease (PAOD) is a serious disease that increases one’s
chance of coronary heart disease. It is caused by atherosclerosis that results in the luminal
stenosis of arteries and reduced blood fl
flow to limb skeletal muscles. Atherosclerosis is the
buildup of plaque in arteries and can lead to chronic ischemia, the decrease in blood flow to
tissue, and impede function in microcirculation ((Figure 1)) [20]. Ischemia due to PAOD often
leads to cramping and pain in skeletal limb muscles due to the insufficient delivery of oxygen
and nutrients. Intermittent claudication, or hypoxic pain during locomotion, is the most common
symptom of PAOD and is intensi
intensified during exercise or stress.

Figure 1: Atherosclerotic plaq
que in an artery. Schematic image comparing a normal artery
and an artery with ath
atherosclerotic plaque buildup [22].
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Treatments for PAOD seek to manage symptoms of the disease, reduce atherosclerotic
plaque, and restore blood flow to ischemic regions. Common treatments include lifestyle
modifications and pharmaceuticals that aim to reduce the intermittent claudication. More
serious cases of PAOD may require stenting or bypass surgery. Bypass surgery involves using
an autologous saphenous vein to bypass the occluded artery and restore blood flow. Yet not all
patients are eligible for bypass surgery due to pre-existing conditions or the lack of a robust vein
to serve as a conduit. Therefore, developing alternate treatments for PAOD is necessary to
benefit all patients. Natural bypass vessels can improve prognosis of patients with PAOD by
providing blood flow around the occluded artery. Collateral vessels provide blood flow to
ischemic areas by bypassing the diseased vessel, and the growth of collateral arteries can be a
life-saving occurrence after an arterial occlusion [18].

Previous Work
Pre-existing collateral networks improve the prognosis of patients with PAOD, but not
all patients have robust collaterals and need an alternative for redirecting blood flow [14].
Animal studies indicate that genetic background strongly influences the number and remodeling
of pre-existing collateral arteries, suggesting that patients who lack robust collaterals may either
lack pre-existing collaterals or exhibit impaired arteriogenesis. The mechanisms of
arteriogenesis are being studied in different models in order to enhance the process of collateral
formation in patients with PAOD [7]. Studies on the microcirculation in different mice strains
show that it is possible to evaluate two types microcirculation networks in Balb/c and C57 mice.
Balb/c mice have a dendritic, unconnected arteriole tree structure whereas C57s have an
arcade structure with many arteriole-to-arteriole connections. Accordingly, with fewer, if any,
pre-existing collaterals, collateral vessels in Balb/c mice form by remodeling at the capillary
2

level after an occlusion [14]. Collateral vessels provide increased blood flow to ischemic areas
of tissue, therefore it is important to understand the formation of arterialized collateral
capillaries in ischemic models lacking pre-existing collaterals.
Arterialized collateral capillaries (ACCs) can form in animals that lack pre-existing
collaterals when an occlusion is present, and allow blood to flow around the occlusion through a
robust capillary [14]. In order for sufficient blood to flow to the ischemic region, the ACCs
must exhibit functional vasodilation, which is impaired at certain time points in animal models
and can prevent sufficient blood flow during strenuous activities [9].
Balb/c mice showed no functional vasodilation in arterialized capillaries 7 days post
ligation, suggesting the ACCs were immature at this time point [3]. Achytalcholine (ECdependent), sodium nitroprusside (SMC-dependent), and norepinephrine (SMC-dependent)
reagents were applied to the spinotrapezius muscle of Balb/c mice, the results from which
suggested that the impairment of vasodilation at 7 days post ligation is due to smooth muscle
cell impairment [9]. It is important to study the impairment of collateral vessels in different
models to understand how recovery from an occlusion can be accelerated.

Endothelial-Dependent Dilation
Bradykinin (BK), isoproterenol (ISO), and sodium nitroprusside (SNP) were applied to
the spinotrapezius muscle of Balb/c mice in a physiological salt solution seven days post
ligation to understand the vascular reactivity in arterialized collateral capillaries. Endothelial
dependent (bradykinin) and endothelial independent (isoproterenol and sodium nitroprusside)
reagents were utilized to test the different pathways that cause smooth muscle cells to relax and
provide functional vasodilation of arterioles. Endothelial cells cause smooth muscle cells to
relax through different pathways [16].
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Bradykinin is an endothelial-dependent agonist that interacts with G protein coupled
receptors (GPCR) at the endothelial cell surface [6]. The binding of BK to the GPCR activates
phospholipase C (PLC) and causes an increase in cytoplasmic calcium and diacylglycerol
(DAG) levels [10,17]. The surplus of intracellular calcium binds to calmodulin (Cam) and
phosphorylates eNOS to promote the synthesis of NO [19]. NO is released into smooth muscle
cells where it binds to soluble guanylyl cyclase receptors (sGC) [7, 4]. The activation of sGC
increases cGMP production, activating protein kinase G (PKG) that phosphorylates myosin
light chain kinase. Phosphorylation inhibits MLCK and decreases the interaction between actin
and myosin, causing relaxation and vasodilation [2]. BK can increase blood flow and improve
myocardial metabolism through vasodilation of microvessels [11].

Figure 2: Endothelial-dependent vasodilation. Bradykinin acts through the GPCR on
endothelial cells in microvasculature to cause dilation of smooth muscle cells [15].
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Previous research examined the impairment of vasodilation in vasculature using
acetylcholine (Ach), another endothelial-dependent agonist that acts through a different signal
transduction pathway. Ach targets the GPCR and activates the protein kinase A (PKA) in the
GPCR cascade [14, 8]. There was no endothelial impairment of vasodilation in immature
arterialized capillaries when stimulated with Ach [9], beyond the smooth muscle cell
impairment that was observed.
Smooth muscle cells in microvasculature are able to relax independently of endothelialderived factors. Smooth muscle cell-dependent dilators, such as epinephrine, acts through betaadrenergic receptors to relax the smooth muscle cells in microvasculature. Beta-adrenergic
receptors are GPCRs, that when stimulated by their agonist, cause the dissociation of the Gα
subunit and the activation of adenylyl cyclase. Adenylyl cyclase (AC) catalyzes the conversion
of ATP into cyclic-AMP (cAMP) and the cAMP phospohorylates cAMP-dependent PKA,
which phosphorylates MLCK. Phosphorylation of the MLCK causes a decrease in activity,
hyperpolarization and relaxation of the smooth muscle cells [12]. Isoproterenol is a nonselective
beta-adrenergic agonist that stimulates beta-receptors and causes relaxation of arterioles by
directly targeting smooth muscle cells.
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Figure 3: Beta-adrenergic signaling cascade. Endothelial-independent dilators cause smooth
muscle cell relaxation through the dissociation of the Gα subunit [21].
Sodium nitroprusside is a smooth muscle cell-dependent vasodilator that bypasses the
endothelial activation of the GPCR. SNP is converted into NO that diffuses directly into the
SMCs and causes vasodilation through an increase in cGMP and the phosphorylation of the
myosin light chain kinase. Sodium nitroprusside acted as a control in this study, as previous
studies have analyzed the effect of SNP on vasodilation of immature arterialized capillaries in
Balb/c mice and saw impaired vascular reactivity through the NO pathway [9].
These reagents were chosen to target specific cell types and extend the work of previous
studies that utilized Ach, SNP and NE to examine impaired vascular reactivity in arterialized
capillaries.
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Specific Aims
It is hypothesized that the impaired vasodilation in immature arterialized collateral
capillaries is due to smooth muscle cell impairment. If the SMC is impaired, we expect to see
similar responses in the ACCs to BK and ISO on the ligated side as well as similar responses
between BK and Ach and ISO and SNP [9]. Arterialized collateral capillary formation can
benefit patients that lack pre-existing collateral networks and to maximize the benefit of
collaterals, the ACCs must be capable of regulating blood flow and exhibiting functional
vasodilation.
Specific Aim 1: To assess the reactivity of terminal arterioles in unoperated mice and
identify the lowest concentration of BK and ISO necessary to achieve maximum vasodilation.
Specific Aim 2: To test the hypothesis that smooth muscle cell-dependent vasodilation is
impaired in arterialized collateral capillaries 7 days post ligation of the lateral feed artery in the
spinotrapezius muscle.

7

METHODS
Animal Care
Male Balb/c mice were used in the procedures in accordance with protocols approved by
the Institutional Animal Care and Use Committee (IACUC) of California Polytechnic State
University, San Luis Obispo. Mice were housed in the University Vivarium and were monitored
daily for food and water levels.

Lateral Feed Artery Ligation
Ligations were performed to occlude the lateral feed artery and induce the formation of
ACCs in the spinotrapzeius muscle. Buprenorphine analgesic (0.075 mg kg-1) was
subcutaneously administered after the mouse was anesthetized with 5% isoflurane in oxygen
flowing at 3-5 l⋅min-1. The mouse was then transferred to the heat pad on the surgical stage
where a nose cone administered ~1-3% isoflurane flowing at 0.5-1.0 l⋅min-1. The heat pad was
set to 35° C for the duration of the procedure and the temperature was monitored with a rectal
probe. The hair on the dorsal region of the mouse was removed prior to the surgery with
clippers and depilatory cream, and veterinary ointment was applied to the corneas to prevent
corneal desiccation.
Using aseptic technique, a small incision was made above the cranial, lateral edge of the
spinotrapezius muscle, where the fat pad overlays the muscle. The fat pad, cranial and
superficial to the spinotrapezius, was blunt dissected to expose the lateral edge; the site was
frequently irrigated with phosphate buffered saline (PBS) to prevent desiccation. The lateral
feed artery was isolated and ligated with single strands from 6-0 silk suture (Figure 2). The
initial incision was closed with 7-0 polypropylene suture. Sham-side surgeries were performed
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to induce similar trauma to the area without ligating the artery. Immediately following surgery,
buprenorphine analgesic was administered subcutaneously (0.075 mg·kg-1). The operated mouse
was returned to the vivarium and given oral buprenorphine (0.01 mg⋅mL-1) for two days
following surgery.

Figure 4: Spinotrapezius artery feed ligation. A. Schematic of spinotrapezius muscle.
B. Balb/c vasculature lacking collaterals [14].

Vascular Reactivity
Seven days post ligation, the spinotrapezius muscle was exposed to vasoactive agents on
both the ligated and sham side to examine endothelial-dependent and endothelial-independent
vasodilation of arterialized collateral capillaries (ACCs).
The mouse was prepared as described above, except the procedure was not performed
aseptically and no analgesic was administered. Figure 5 displays the experimental configuration
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and a schematic including the flow parameters.
An initial incision was made at the right caudal region of the spinotrapezius muscle and
the incision was extended along the distal portion of the muscle to reveal the muscle. The
connective tissue above the spinotrapezius muscle was removed using micro-dissection scissors
and fine forceps. During the procedure, the muscle was continually irrigated with physiological
salt solution (PSS) at a flow rate of ~2 mL min-1. The PSS was deoxygenated with 5% CO2 –
95% N2 and warmed to 35° C.
After the connective tissue was removed, the intravital microscope (Microscan
MIcrovision Medical) was placed over the muscle to visualize the microvasculature of the
muscle, and the surgical stage was adjusted to locate the area of interest on the muscle. A 30minute equilibration period was undergone between dissection and the addition of the first
dilator as well as in between the addition of each dilator to allow the vessels to return to rest. In
the pilot study, different concentrations, from 10-8 to 10-4, were added with a micropipette to the
PSS for both Bradykinin and Isoproterenol, with a five minute wait period between each
concentration—recordings were taken at each time point—and the reactivity of the terminal
arterioles was determined. In the second study, the optimal amount, 10-5 M, of each vasoactive
agent (bradykinin, isoproterenol, and sodium nitroprusside) was added to the PSS to study the
reactivity of the arterialized collateral capillaries. Ten-second videos were recorded before, and
five minutes after the addition of each reagent. The same procedure was followed for the sham
side, following the lateral feed artery to examine terminal arterials of similar size. Upon
completion, the mouse was euthanized by cervical dislocation.
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Figure 5: Intravital microscopy superfusion sset-up. A. Representative image of preparation
with microscan and heated syringe. B. Close up of mouse with heat pad and Microscan.
C. Schematic of flow.

Imaging and Statistical Analysis
Automated Vascular Analysis ((AVA) software was used to stabilize the videos and
conduct measurements of the arteriole diameter. Measurements were performed on the
stabilized images to determine the difference in arteriole diameter before and after exposure to
the reagents. Statistical analysis
alysis was performed on the data generated from the images in the
AVA software to compare the diameters for the varying concentrations of reagents
reagent and time
points as well as to compare the diameter changes on the operated and sham sides.
sides One-way
ANOVA tests were performed on the data, with post
post-hoc
hoc Tukey’s tests used to determine the
location of significant differences.
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RESULTS
The first objective of the project was to complete a pilot study that involved measuring the
vasodilation of small terminal arterioles in response to increasing doses of isoproterenol (SMC
dep) and bradykinin (EC dep), 10-7 to 10-4 M, and sodium nitroprusside (SMC dep) to identify
the lowest concentration necessary to achieve a maximum dilation, Figure 6. Swiss-Webster
mice from the Cal Poly colony were used to conduct the pilot study due to similarity to Balb/c
mice and easy availability.
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Figure 6: Superfusion dosage response in unoperated mice. Line graph displays change in
diameter (µm) before and after log-increasing doses of bradykinin (BK) and isoproterenol (ISO)
(n=5).
Based on the results from the pilot study, we determined that the optimal concentration
for both bradykinin and isoproterenol was 10-5M, which represented the plateau of the dose
response “S” curve, in which diameter did not significantly increase with the next log dilution
(determined after running repeated measures ANOVA for each reagent). Sodium nitroprusside
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was previously determined to have optimal vascular reactivity at 10-5 M [9]. After completing
the pilot study, the main objective of this project was to test the hypothesis that smooth muscledependent vasodilation is impaired in immature arterialized capillaries. At day 7 following
lateral feed artery ligation, we measured vasodilation of arterialized collateral capillaries in
response to 10-5 M BK, ISO and SNP, Figure 7.
On the sham side, the vasoactive agents induced significant vasodilation from rest (7 ±
0.5 µm) when exposed to BK (12 ± 0.5 µm), ISO (13 ± 0.5 µm) and SNP (12 ± 0.5 µm). The
arterialized collateral capillaries on the ligated side also experienced vasodilation from rest (7 ±
0.5 µm) when exposed to BK, ISO, and SNP. Although the ACCs vasodilated in response to the
vasoactive agents, for ISO there was less dilation on the ligated side (10 ± 1 µm) compared to
dilated diameter on the sham side (13 ± 0.5 µm). For SNP, there was also a significant decrease
in dilated diameter on the ligated side (10 ± 0.5 µm) compared to the sham side (12 ± 1 µm),
Figure 7.
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Figure 7:: Vascular reactivity of arterialized collateral capillaries. A. Representative image
of an arterialized collateral capillary pre and post exposure to BK. B. Diameters (um) pre and
post exposure to 10-5 M BK (n=7). C. Diameters (µm) pre and post exposure to 10-5 M ISO
(n=7). D. Diameters (µm) pre and post exposure to 10-5 SNP (n=5). * p<0.05 difference from
baseline. + p<0.05 difference between sham and ligated
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The percent change of each vessel diameter was compared on the sham and ligated side
to determine if there was impaired vasodilation in the immature arterialized collateral
capillaries, Figure 8.
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Figure 8:: Relative reactivity of arterialized collateral capillaries. Percent change in diameter
before and after exposure to BK (n=7), ISO (n=7), and SNP (n=5). * p<0.05 for sham versus
ligated.
When exposed to bradykinin, the terminal arterioles on the sham side had a larger
larg
percent change in diameter (80 ± 5)) compared to the arterialized collateral capillaries on the
ligated side (44 ± 7).
). In response to the isoproterenol, the terminal arterioles on the sham side
had a larger percent change in diameter ((79 ± 6) compared to the ACCs on the ligated side (44 ±
7).
). Sodium nitroprusside also elicited a larger percent change in diameter of the terminal
arterioles (99 ± 7) compared to the ACCs (36 ±8).
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DISCUSSION
Clinical Significance
Peripheral arterial occlusive disease can lead to chronic ischemia and intermittent
claudication due to a plaque buildup in limb arteries. Collateral vessels can act as natural
bypasses to provide improved blood to this ischemic region flow for patients with POAD, but
pre-existing collateral networks are not always present in patients with ischemia. In animal
models of chronic ischemia, arterialization of collateral capillaries, by arteriogenesis, can
restore blood flow to the ischemic region. However, to provide sufficient blood flow, the
collateral vessels must exhibit functional vasodilation, the vessels must be able to dilate in
response to increased tissue metabolism. Arterialized collateral capillaries in Balb/c mice have
impaired vasodilation 7 days post artery ligation, but dilate normally at day 21 [9]. The goal of
this study was to confirm the impaired smooth muscle cell-dependent responses in the
arterialized collateral capillaries.

Vascular Reactivity
Endothelial cell-dependent vasodilation was tested using bradykinin, an endothelialdependent agonist. The immature arterialized collateral capillaries exposed to bradykinin
showed significant, but impaired vasodilation compared to the terminal arterioles on the sham
side. Bradykinin targets the GPCRs on the endothelial cells lining the arteriole wall and through
the GPCR cascade, causes the formation of nitric oxide, which is released into the smooth
muscle cells and causes relaxation. It is unknown which part of the pathway is inhibited and
further testing of the endothelial-dependent pathway should be tested. Specifically the GPCR
cascade in the endothelial cell, separate from the smooth muscle cell response, should be tested
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to confirm impairment of the endothelial-dependent vasodilation. The results do not confirm or
refute impaired vascular reactivity due to endothelial cell impairment.
Smooth muscle cell-dependent agonists, isoptorterenol and sodium nitroprusside, which
cause vasodilation in microvasculature, were applied onto immature arterialized collateral
capillaries at day 7 following an artery occlusion. The decrease in vascular reactivity in the
ACCs compared to the terminal arterials indicates that smooth muscle cells are impaired in
immature arterialized collateral capillaries 7-days post ligation. SNP and ISO cause vasodilation
through different pathways in the smooth muscle cells; SNP breaks down into NO which
increases cGMP and leads to the phosphorylation of MLCK, whereas ISO targets the betaadrenergic receptor to activate adenylyl cyclase, increase cAMP and ultimately phosphorylate
the MLCK to prevent contraction and induce vasodilation. The results indicate that both types
of pathways that lead to vasodilation in the immature arterialized collateral capillaries are
impaired. SNP had a larger trending change in percent difference from sham to ligated, but
showed no significant difference compared to ISO, which could indicate that the pathways have
various levels of impairment.
By testing the vascular reactivity of the arterialized collateral capillaries in response to
bradykinin, isoproterenol, and sodium nitroprusside, we were able to determine that the smooth
muscle cells at day 7 following an artery ligation contribute to impaired vasodilation, but it is
unknown what causes impairment of vascular smooth muscle cells.

Smooth Muscle Cell Phenotype
Vascular smooth muscle cells (VSMC) are categorized based on contractile properties,
with considerable phenotypic diversity in various vessels throughout the body [5]. VSMC
phenotype is related to varying developmental origins and can be influenced by the outward
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remodeling of the vessel due to arteriogenesis [18, 16]. Structural remodeling could contribute
to different smooth muscle contractile phenotypes and reduced vasodilation capacity.
Arterialization of the capillaries occurs when capillaries recruit smooth muscle cells and
gain the ability to dilate and contract, but the contractile ability is not fully functional at the
onset of arteriogenesis. Changes in the myosin light chain and myosin heavy chain during the
remodeling phase could enhance the vessels response to external stimuli with respect to the
regulation of blood flow [5]. Different vessels express various phenotypes that allow for
different levels of vasomotion and vascular smooth muscle phenotype may be driven by
innervation, load, or other varying external signal [5].

Future Work
To understand why smooth muscle cells are impaired in ACCS at day 7 following an
artery ligation, future research should study the remodeling of the vascular smooth muscle cells
and the changes in the myosin light chain and myosin heavy chain isoforms during
arteriogenesis. Impairment of the vasodilation could be due to the change in phenotype and
migration of SMCs to the capillaries during arterialization and remodeling [18].
Examining vascular remodeling at the cellular level would help explain the lack of
functional vasodilation by understanding how the cells are arranged and changing between day
7 and day 21 after arterialization of the collateral capillary.

Limitations
One limitation in this experiment was the accuracy of the dosage response curves
created in the first part of the study. There was a large standard error associated with the
vascular reactivity of both the BK and ISO reagents on terminal arterioles in the unoperated
mice. It is possible that in the arterialized collateral capillaries there was normal vasodilation at
18

lower doses and only impaired vasodilation at higher doses, thus changing the interpretation of
the data in the first part of the study. An inaccuracy in selecting the optimized dosage could
have resulted in a discrepancy in the percent change of the ACC diameter.

Summary
Functional vasodilation in immature arterialized collateral capillaries is impaired, to
some extent, due to smooth muscle cell impairment at day 7 following occlusion of the lateral
feed artery. The impairment of smooth muscle cells in the newly formed collateral vessels can
hinder the recovery of ischemia and fail to match blood flow with tissue metabolic demand. If
the smooth muscle cell recruitment and regeneration is better understood, it may be possible to
induce the formation of mature, functional arterialized collateral capillaries after an occlusion.
Therefore, understanding the cause of impairment is important to more effectively increase
blood flow to the ischemic region, reduce the duration of impaired vasodilation, and may
provide the foundation for future treatments for patients with PAOD.
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APPENDIX
Vascular Reactivity checklist and protocol
Date ______________

Intravital Microscopy with Superfusion

Mouse Information
DOB: ______________________
Sex: _______________________
Tag: _______________________
Genotype/strain: _____________
Cage: ______________________
Weight: ____________________
Materials
____1.
forceps (1)
____2. fine forceps (1)
____3. ultrafine forceps (2)
____4. fine scissors (1)
____5. ultrafine scissors (1)
____6. 60mL syringe
____7. bubbler (2)
____8. volumetric flask
____9. Kim wipes
____10. Vasodilator/vasoconstrictor
____11. 20X PSS
____12. 20X NaHCO3
____13. non-sterile cotton swabs
____14. non-sterile cotton gauze
____15. 10mL Graduated cylinder
____16. stopwatch
Instrument Preparation
____17. Turn on ultrasonic bath to 45ºC
____18. Transfer 50mL of 20x PSS into 1L volumetric
flask
____19. Transfer 50mL of 20x NaHCO 3 into 1L volumetric
flask
____20. Dilute PSS & NaHCO3 to 1L with 18MΩ H20
____21. Place 1L volumetric flask in water bath, using
weight if necessary
____22. Fill syringe in syringe heater with 50mL of 1x PSS
& turn on syringe heater
____23. Place thermister in syringe heater
____24. Weigh out or thaw vasodilator
Surgery preparation
____25. Weigh animal in weight boat
____26. Place animal in anesthesia box
____27. Open the oxygen cylinder and set anesthesiamachine flow meter to ~3 l·min-1
____28. Anesthetize animal w/ 5% isoflurane
____29. Reduce flow rate to 0.5-1.0 l·min-1 and the
isoflurane to 1-3%
____30. Lay animal supine on preparation bench with nose
in nose-cone
____31. Use trimming clippers & depilatory cream to
remove hair superficial to spinotrapezius
____32. Transfer mouse to stage on FST heat pad
____33. Insert rectal probe and set thermo-controller to
35°C

Initials ___________

____34. Open stopcock on delivery tubing to check flow
rate of superfusion solution and use thermister to
measure temperature
____35. Adjust flow rate or temperature to achieve
~2mL·min-1 and ~35ºC at tip
Measurement preparation
____36. Make an incision (1cm) at the caudal end of the
spinotrapezius
____37. Extend the incision cranially to the fat pad,
creating a horse shoe incision
____38. Blunt dissect the subcutaneous connective tissue to
maximize surgical exposure
____39. Maximize visibility of muscular branch- minimize
contact/trauma of the artery
Intravital Microscopy
____40. Recheck flow rate and temperature of supefusion
solution
____41. Place microscan in stand and insure proper
connectivity to computer.
____42. Open AVA and create new folder containing date
of procedure and make current folder.
____43. Select capture on AVA main menu for microscan
imaging
____44. Label patient I.D. with the number of patient first
followed by left or right hind limb or sham for
control hind limb.
EX: 25LeftACh8
____45. Locate muscular branch and adjust microscan for
best resolution.
____46. Position superfusion delivery tubing with ballbearing manipulator at microscan lens to ensure
flow over the artery
____47. Place kim-wipe wick on side of animal (avoid
contact with muscle)
____48. Use AVA to measure muscular branch diameter
after 30 minutes of stabilization.
____49. Ensure that 60mL syringe contains 60mL of PSS
____50. Add dose of first vasodilator agent
____51. Allow superfusion to flow for 5 minutes and
record video in the final minute
____52. Empty 60mL syringe, rinse with 18MΩ H2O
____53. Refill syringe with 60mL of PSS and repeat
superfusion with 2nd and 3rd vasoactive agents
____54. Repeat procedure on the contralateral limb
Analysis
____55. Open analysis section in AVA and open file of
interest
____56. Set Frames from 0 to 160 and stabilize file
____57. Analyze vessel diameter by manually drawing
diameter and chaining sections together
____58. Record results in provided table
Post-Experiment
____59. Cervical dislocation to euthanize animal
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Date ______________

Intravital Microscopy with Superfusion

____60. Rinse superfusion line (bubbler, superfusion tubing,
syringe, & side-arm flask) with water (flush tubing
w/ syringe)
____61. Flush superfusion line with 1M HCl & rinse with
water
____62. Flush superfusion line with 18MΩ H2O

Initials ___________

Limb 1
Left or Right
BK Resting Diameter_____________________________ _
BK volume & concentration________________________ _
BK dose 1 Diameter_______________________________
ISO Resting Diameter_____________________________ _
ISO volume & concentration _______________________
ISO Diameter ________________________________ ____
SNP Resting Diameter_____________________________
SNP volume & concentration _______________________
SNP Diameter ________________________________ ___

Limb 2
Left or Right
BK Resting Diameter_____________________________ _
BK volume & concentration________________________ _
BK dose 1 Diameter_______________________________
ISO Resting Diameter______________________________
ISO volume & concentration _______________________
ISO Diameter ________________________________ ____
SNP Resting Diameter_____________________________
SNP volume & concentration _______________________
SNP Diameter ________________________________ ___

Notes
________________________________ _______________
________________________________ _______________
________________________________ _______________
________________________________ _______________
________________________________ _______________
________________________________ _______________
________________________________ _______________
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